Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism

The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels,...

Full description

Bibliographic Details
Main Authors:	Masanori Tokumoto, Shin Tokunaga, Shinji Asada, Yuichi Endo, Noriaki Kurita, Masafumi Fukagawa, Tadao Akizawa
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746983/?tool=EBI

Similar Items

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
by: Takashi Shigematsu, et al.
Published: (2022-01-01)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
by: Shigematsu T, et al.
Published: (2020-05-01)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
by: Keitaro Yokoyama, et al.
Published: (2019-04-01)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
by: Shigematsu T, et al.
Published: (2018-09-01)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
by: Tadao Akizawa, et al.
Published: (2018-01-01)

Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
by: Mariko Sakai, et al.
Published: (2020-01-01)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
by: Keitaro Yokoyama, et al.
Published: (2017-07-01)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study.
by: Shinji Asada, et al.
Published: (2019-01-01)

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism
by: Chihiro Kato, et al.
Published: (2020-10-01)

Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
by: Nobuo Nagano, et al.
Published: (2024-03-01)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
by: Fumihiko Koiwa, et al.
Published: (2018-01-01)

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
by: Motoko Tanaka, et al.
Published: (2016-01-01)

Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma
by: Azusa Morishita, et al.
Published: (2023-01-01)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
by: Fumihiko Koiwa, et al.
Published: (2023-11-01)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
by: Takatoshi Kakuta, et al.
Published: (2020-02-01)

THE CARDIOVASCULAR EFFECTS OF CINACALCET IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
by: Sungjin Chung, et al.
Published: (2012-06-01)

Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.
by: Suguru Yamamoto, et al.
Published: (2015-01-01)

Chronic inflammation in hemodialysis patients with secondary hyperparathyroidism
by: I.O. Dudar, et al.
Published: (2022-06-01)

Nutritional status of hemodialysis patients with secondary hyperparathyroidism
by: L.T.T. Rezende, et al.
Published: (2000-11-01)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
by: Brett Hauber, et al.
Published: (2017-07-01)

Myringosclerosis in hemodialysis patients with hyperparathyroidism
by: Alsayed Alnahal, et al.
Published: (2020-01-01)

Secondary hyperparathyroidism in diabetic kidney disease patients treated with hemodialysis
by: I.O. Dudar, et al.
Published: (2023-01-01)

Parathyroid gland tuberculosis associated with secondary hyperparathyroidism in hemodialysis patient
by: Kabbaj Driss, et al.
Published: (2010-01-01)

Influence of secondary hyperparathyroidism in management anemia in patients on regular hemodialysis
by: Hamzagić Nedim, et al.
Published: (2020-01-01)

Parathyroidectomy Reduces Intradialytic Hypotension in Hemodialysis Patients with Secondary Hyperparathyroidism
by: Chia-Jen Shih, et al.
Published: (2013-09-01)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
by: Eidman KE, et al.
Published: (2018-02-01)

Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients
by: Salah O Bashir, et al.
Published: (2015-01-01)

Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study
by: Gojaseni P, et al.
Published: (2017-02-01)

Efficacy and Safety of Etelcalcetide in Hemodialysis Patients with Moderate to Severe Secondary Hyperparathyroidism
by: Paola Monciino, et al.
Published: (2022-09-01)

Fibrous dysplasia in maxilla in a patient on hemodialysis with severe secondary hyperparathyroidism
by: Hui-Hsin Yang, et al.
Published: (2022-05-01)

Association of Secondary Hyperparathyroidism with Coronary Artery Disease in Patients on Regular Hemodialysis
by: Azar BARADARAN, et al.
Published: (2011-12-01)

The Effectiveness of Alternate-day Cinacalcet Therapy for Secondary Hyperparathyroidism in Noncompliant Hemodialysis Patients
by: Mohammed Al-Homrany, et al.
Published: (2022-01-01)

Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
by: Wenqiang Qiu, et al.
Published: (2023-08-01)

The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis
by: Randon R.B., et al.
Published: (2005-01-01)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
by: Geoffrey A Block, et al.
Published: (2019-01-01)

Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects
by: He X, et al.
Published: (2024-02-01)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
by: Keiichi Otsuka, et al.
Published: (2018-10-01)

Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism
by: Mohamed Mimi Abd Elgawwad El-kholey, et al.
Published: (2019-12-01)

Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
by: M Malek, et al.
Published: (2004-01-01)

Severe hyperparathyroidism is associated with nutritional impairment in maintenance hemodialysis patients
by: Sinee Disthabanchong, et al.
Published: (2022-09-01)